Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Investing

European shares end lower as UBS unveils Archegos hit, travel stocks soar

European stocks weighed down by UBS' Archegos hit, BP surges

By Sruthi Shankar and Ambar Warrick

(Reuters) -European stocks ended a shade lower on Tuesday as optimism over strong British earnings was offset by UBS disclosing a hit from dealing with U.S. investment firm Archegos, while travel stocks hit record highs on hopes of a post-COVID rebound.

The pan-European STOXX 600 index slipped 0.1%, with investors holding off big bets ahead of the U.S. Federal Reserve’s policy decision on Wednesday. The bank is widely expected to maintain easy monetary policy.

Oil major BP rose 0.4% after its first-quarter profit soared and it planned share buybacks, while Asia-focused lender HSBC gained 4.2% after it reported an upbeat quarterly profit.

Meanwhile, UBS fell 2.0% to a two-month closing low as it took an unexpected $774 million hit from Archegos, overshadowing a forecast-beating 14% rise in quarterly net profit.

Still, markets were caught in a tight trading range as investors watched for any clues on the timing of the Fed’s eventual policy tightening, which the bank has said will depend on employment and inflation levels.

“Ultimately, the exact timing of tapering will be a judgement call by the Fed,” Unicredit analysts said.

“They will likely want to see a sequence of better data on jobs and economic activity that substantially reduces the ‘gaps’ to pre-crisis levels, reinforced by a sustainable improvement in the health situation.”

Global stocks have hit record highs recently on optimism about a economic recovery as the pace of vaccination picked up across developed economies.

European travel stocks shared this sentiment, surging 3.0% to close at a record high. Bank stocks also ended higher on upbeat earnings, as well as support from increasing euro zone bond yields. [GVD/EUR]

About a quarter of STOXX companies are set to publish earnings this week. Among the 17% that have reported so far, 65% topped profit estimates, according to Refinitiv IBES data.

Sweden’s Evolution Gaming Group jumped 14.5% to the top of the STOXX 600, as it reported a 150% jump in quarterly core earnings as the COVID-19 pandemic boosted demand for online casino games.

Danish freight forwarder DSV Panalpina surged 6.8% after it agreed to buy the logistics division of Kuwait’s Agility Public Warehousing Co in a deal worth $4.1 billion.

French diagnostics group Biomerieux fell 6.9% to the bottom of the STOXX 600 after it halved its sales outlook for the first half of the year as the easing pandemic looked to cut demand.

(Reporting by Sruthi Shankar in Bengaluru; Editing by Shounak Dasgupta)

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review │ Banking │ Finance │ Technology. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post